How to Order
Form
Who We Are
Leadership
Careers
Investors
Media
News
Events
Contact Us
Products
Tutivia™
Clarava™
Protega™
How to Order
Technology
Background
RNA Signatures
Sequencing
Professionals
Clinical Data
CLIA Lab
Patients
Patient Journey
Partners
AKF
ASN
AST
ASTS
KDIGO
NKF
All Resources
Publications
Videos Resources
Products
Tutivia™
Clarava™
Protega™
How to Order
Technology
Background
RNA Signatures
Sequencing
Professionals
Clinical Data
CLIA Lab
Patients
Patient Journey
Partners
AKF
ASN
AST
ASTS
KDIGO
NKF
All Resources
Publications
Videos Resources
How to Order
Form
Who We Are
Leadership
Careers
Investors
Media
News
Events
Contact Us
News
TR-1: Standard form for notification of major holdings
March 15, 2022
Notification of major holdings
Keep Reading
Close of Subscription and Fundraise Update
March 11, 2022
The Subscription has now closed and the Fundraise has successfully concluded, save for Admission.
Keep Reading
Fundraise - Successful Placing
March 4, 2022
Verici Dx is pleased to announce the successful completion of the Placing.
Keep Reading
Close of Accelerated Bookbuild
March 4, 2022
Further to the announcement made at 7.10 a.m. today, the Placing has now closed and the Bookbuild has been successfully concluded.
Keep Reading
Proposed Fundraise to raise not less than £10.0 million (approximately $13.3 million)
March 4, 2022
Verici Dx announces its intention to conduct a fundraise through the non pre-emptive issue of at least 28,571,429 new ordinary shares
Keep Reading
Successful completion of analytical validation for Clarava™ and Tuteva™
February 15, 2022
Lead products meet comprehensive requirements at CLIA-certified laboratory, representing an important milestone towards commercialisation
Keep Reading
Verici Dx CEO Sara Barrington speaks at Edison Open House: Global Healthcare 2022
January 28, 2022
Sara Barrington, CEO of Verici Dx, interviews with Edison Open House
Keep Reading
Investor Presentation
January 14, 2022
CEO Sara Barrington and CFO David Anderson will provide a live progress and strategy update presentation
Keep Reading
Progress and strategy update
January 12, 2022
Verici Dx provides the following corporate update for the year ended 31 December 2021.
Keep Reading
Clarava
™
and Tuteva
™
complete testing requirements for completion of clinical validation study
January 6, 2022
Primary data analysis of two lead products on track for Q1 2022 read-out
Keep Reading
« Previous
1
2
3
4
5
6
Next »
Archived News
© 2023 Verici Dx
Privacy Policy
|
Clinical Trials Privacy Policy
|
Cookie Policy
Search for:
close
chevron-down
twitter-square
linkedin-square
bars
cross
menu
chevron-down